COMBIVIR

LOE Approaching

lamivudine and zidovudine

GSK
NDAORALTABLETPriority Review
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11

Mechanism of Action

Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Indications (2)

combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infectioncombination with other antiretroviral agents for the treatment of HIV‑1 infection

Clinical Trials (5)

NCT01597648Phase 1Completed

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

Started Nov 2011
42 enrolled
Infection, Human Immunodeficiency Virus I
NCT01275625Phase 4Completed

Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia

Started Jun 2011
98 enrolled
HIV
NCT00960622Phase 4Completed

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

Started Aug 2006
17 enrolled
HIV
NCT00104429Phase 2Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

Started Jan 2005
125 enrolled
Infection, Human Immunodeficiency Virus IHIV Infection
NCT00323544Phase 3Completed

SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

Started Oct 2004
220 enrolled
HIV Infections
Company
GSK
GSK
LONDON, United Kingdom
695 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers